AngioDynamics (ANGO) Tops Q2 EPS by 4c, Revenues Miss; Offers FY20 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results
January 7, 2020 7:00 AM ESTFiscal 2020 Second Quarter Highlights
Net sales of $70.0 million, flat compared to the prior-year quarter Gross margin increased 140 basis points year over year to 59.3% GAAP loss per share of $0.07; adjusted earnings per share of $0.06 Announces the acquisition of C3 Wave PICC tip location system subsequent to quarter end
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc.(NASDAQ: ANGO),a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and... More
